Edition:
United Kingdom

Astellas, Fibrogen Announce Topline Results From Japan Phase 3 Study Of Roxadustat


Thursday, 31 May 2018 

May 31 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS & FIBROGEN ANNOUNCE TOPLINE RESULTS FROM DOUBLE-BLIND JAPAN PHASE 3 STUDY FOR ROXADUSTAT IN HEMODIALYSIS CHRONIC KIDNEY DISEASE PATIENTS WITH ANEMIA.ASTELLAS PHARMA INC - FOURTH JAPAN PHASE 3 STUDY FOR ROXADUSTAT MET ITS PRIMARY ENDPOINT.ASTELLAS PHARMA INC - ROXADUSTAT WAS WELL TOLERATED IN STUDY.ASTELLAS PHARMA INC - SAFETY PROFILE OF ROXADUSTAT WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUS STUDIES BOTH IN DIALYSIS AND NON-DIALYSIS PATIENTS.